tetano
Editor, Senior Moderator
Virol J
. 2022 Dec 15;19(1):218.
doi: 10.1186/s12985-022-01944-6.
Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
Xuejiao Liao[SUP] #[/SUP][SUP] 1 [/SUP], Dapeng Li[SUP] #[/SUP][SUP] 1 [/SUP], Jie Liu[SUP] #[/SUP][SUP] 2 [/SUP], Zhi Liu[SUP] 3 [/SUP], Zhenghua Ma[SUP] 1 [/SUP], Jingke Dong[SUP] 1 [/SUP], Xiangyi Yang[SUP] 1 [/SUP], Dan Shu[SUP] 1 [/SUP], Jing Yuan[SUP] 1 [/SUP], Lei Liu[SUP] 4 5 [/SUP], Zheng Zhang[SUP] 6 7 8 [/SUP]
Affiliations
Abstract
Background: Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy.
Methods: We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome.
Results: In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels.
Conclusion: The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.
Keywords: Antibody therapy; COVID-19; Clinical manifestation; Delta variant; SARS-CoV-2.
. 2022 Dec 15;19(1):218.
doi: 10.1186/s12985-022-01944-6.
Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
Xuejiao Liao[SUP] #[/SUP][SUP] 1 [/SUP], Dapeng Li[SUP] #[/SUP][SUP] 1 [/SUP], Jie Liu[SUP] #[/SUP][SUP] 2 [/SUP], Zhi Liu[SUP] 3 [/SUP], Zhenghua Ma[SUP] 1 [/SUP], Jingke Dong[SUP] 1 [/SUP], Xiangyi Yang[SUP] 1 [/SUP], Dan Shu[SUP] 1 [/SUP], Jing Yuan[SUP] 1 [/SUP], Lei Liu[SUP] 4 5 [/SUP], Zheng Zhang[SUP] 6 7 8 [/SUP]
Affiliations
- PMID: 36522677
- DOI: 10.1186/s12985-022-01944-6
Abstract
Background: Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy.
Methods: We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome.
Results: In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels.
Conclusion: The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.
Keywords: Antibody therapy; COVID-19; Clinical manifestation; Delta variant; SARS-CoV-2.